Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis

ABSTRACTToday, more than 90% of people with cystic fibrosis (pwCF) are eligible for the highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy called elexacaftor/tezacaftor/ivacaftor (ETI) and its use is widespread. Given the drastic respiratory symptom improve...

Descrición completa

Detalles Bibliográficos

Principais autores:	Catherine R. Armbruster, Yasmin K. Hilliam, Anna C. Zemke, Samar Atteih, Christopher W. Marshall, John Moore, Junu Koirala, Leah Krainz, Jordan R. Gaston, Stella E. Lee, Vaughn S. Cooper, Jennifer M. Bomberger
Formato:	Artigo
Idioma:	Inglês
Publicado:	American Society for Microbiology 2024-05-01
Series:	mBio
Assuntos:	cystic fibrosis Pseudomonas aeruginosa evolution pathogenesis respiratory pathogens lung infection
Acceso en liña:	https://journals.asm.org/doi/10.1128/mbio.00519-24
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!